FABP5 and obesity disorder: FABP5 drives obesity-induced hepatocellular carcinoma by promoting lipid peroxidation resistance and immunosuppression, while its inhibition induces ferroptosis and a pro-inflammatory tumor microenvironment, offering a potential therapeutic strategy.